Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' LEVY RH' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 56 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Hansten, PD; Levy, RH
      Role of P-glycoprotein and organic anion transporting polypeptides in drugabsorption and distribution - Focus on H-1-receptor antagonists

      CLINICAL DRUG INVESTIGATION
    2. Ragueneau-Majlessi, I; Levy, RH; Meyerhoff, C
      Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin

      EPILEPSY RESEARCH
    3. Levy, RH; Ragueneau-Majlessi, I; Baltes, E
      Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers

      EPILEPSY RESEARCH
    4. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
      Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)

      EPILEPSY RESEARCH
    5. Yao, CP; Kunze, KL; Kharasch, ED; Wang, Y; Trager, WF; Ragueneau, I; Levy, RH
      Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    6. Mather, GG; Labroo, R; Le Guern, ME; Lepage, F; Gillardin, JM; Levy, RH
      Nefopam enantiomers: Preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration

      CHIRALITY
    7. Wang, XY; Levy, RH; Ho, RJY
      Development of a semi-quantitative assay to detect full-length CYP2C19 RNA

      BIOTECHNIQUES
    8. Spiegelstein, O; Kroetz, DL; Levy, RH; Yagen, B; Hurst, SI; Levi, M; Haj-Yehia, A; Bialer, M
      Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid

      PHARMACEUTICAL RESEARCH
    9. Levy, RH
      Reply to David Wyman (Bombing of Auschwitz)

      HOLOCAUST AND GENOCIDE STUDIES
    10. Rettie, AE; Haining, RL; Bajpai, M; Levy, RH
      A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin

      EPILEPSY RESEARCH
    11. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
      Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)

      EPILEPSY RESEARCH
    12. Finnell, RH; Bennett, GD; Mather, GG; Wlodarczyk, B; Bajpai, M; Levy, RH
      Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model

      REPRODUCTIVE TOXICOLOGY
    13. Spiegelstein, O; Yagen, B; Levy, RH; Finnell, RH; Bennett, GD; Roeder, M; Schurig, V; Bialer, M
      Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid

      PHARMACEUTICAL RESEARCH
    14. Erickson, DA; Mather, G; Trager, WF; Levy, RH; Keirns, JJ
      Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

      DRUG METABOLISM AND DISPOSITION
    15. Shen, DD; Levy, RH
      Valproate

      ANTIEPILEPTIC DRUGS
    16. Yao, CP; Mather, GG; Stephens, JR; Levy, RH
      Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha - Implication for valproic acid-associated hepatotoxicity syndrome

      BIOCHEMICAL PHARMACOLOGY
    17. BIALER M; LEVY RH; PERUCCA E
      DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE

      Therapeutic drug monitoring
    18. Wilson, GS; Harwood, DM; Askin, RA; Levy, RH
      Late Neogene Sirius Group strata in Reedy Valley, Antarctica: a multiple-resolution record of climate, ice-sheet and sea-level events

      JOURNAL OF GLACIOLOGY
    19. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
      CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996)

      Epilepsy research
    20. GLUE P; BANFIELD CR; PERHACH JL; MATHER GG; RACHA JK; LEVY RH
      PHARMACOKINETIC INTERACTIONS WITH FELBAMATE - IN-VITRO IN-VIVO CORRELATION

      Clinical pharmacokinetics
    21. HETTINGER ME; GILL DJ; ROBIN JB; LEVY RH; KOESTER J
      EVALUATION OF DICLOFENAC SODIUM 0.1-PERCENT OPHTHALMIC SOLUTION IN THE TREATMENT OF OCULAR SYMPTOMS AFTER BILATERAL RADIAL KERATOTOMY

      Cornea
    22. LEVY RH
      A NEW PERSPECTIVE ON THE ESSAY, THE BOMBING OF AUSCHWITZ, A CRITICAL ANALYSIS

      American Jewish history
    23. MORGANROTH J; LYNESS WH; PERHACH JL; MATHER GG; HARR JE; TRAGER WF; LEVY RH; ROSENBERG A
      LACK OF EFFECT OF AZELASTINE AND KETOCONAZOLE COADMINISTRATION ON ELECTROCARDIOGRAPHIC PARAMETERS IN HEALTHY-VOLUNTEERS

      Journal of clinical pharmacology
    24. MARTIN SW; BISHOP FE; KERR BM; MOOR M; MOORE M; SHEFFELS P; RASHED M; SLATTER JG; BERTHONCEDILLE L; LEPAGE F; DESCOMBE JJ; PICARD M; BAILLIE TA; LEVY RH
      PHARMACOKINETICS AND METABOLISM OF THE NOVEL ANTICONVULSANT AGENT ,6-DIMETHYLPHENYL)-5-METHYL-3-ISOXAZOLECARBOXAMIDE (D2624) IN RATS AND HUMANS

      Drug metabolism and disposition
    25. STILWELL JD; LEVY RH; FELDMANN RM; HARWOOD DM
      ON THE RARE OCCURRENCE OF EOCENE CALLIANASSID DECAPODS (ARTHROPODA) PRESERVED IN THEIR BURROWS, MOUNT-DISCOVERY, EAST ANTARCTICA

      Journal of paleontology
    26. ROSENFELD WE; LIAO S; KRAMER LD; ANDERSON G; PALMER M; LEVY RH; NAYAK RK
      COMPARISON OF THE STEADY-STATE PHARMACOKINETICS OF TOPIRAMATE AND VALPROATE IN PATIENTS WITH EPILEPSY DURING MONOTHERAPY AND CONCOMITANT THERAPY

      Epilepsia
    27. TRAN A; REY E; PONS G; ROUSSEAU M; DATHIS P; OLIVE G; MATHER GG; BISHOP FE; WURDEN CJ; LABROO R; TRAGER WF; KUNZE KL; THUMMEL KE; VINCENT JC; GILLARDIN JM; LEPAGE F; LEVY RH
      INFLUENCE OF STIRIPENTOL ON CYTOCHROME P450-MEDIATED METABOLIC PATHWAYS IN HUMANS - IN-VITRO AND IN-VIVO COMPARISON AND CALCULATION OF IN-VIVO INHIBITION CONSTANTS

      Clinical pharmacology and therapeutics
    28. MATHER GG; HARR JH; HARGREAVES JA; TRAGER WF; LEVY RH
      LACK OF HUMAN CYP450 INHIBITION BY TIZANIDINE AND 2 MAJOR METABOLITES

      Clinical pharmacology and therapeutics
    29. LEVY RH
      THE BOMBING OF AUSCHWITZ REVISITED - A CRITICAL ANALYSIS

      Holocaust and genocide studies
    30. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
      PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE

      Epilepsy research
    31. LEVY RH
      SEDATION IN ACUTE AND CHRONIC AGITATION

      Pharmacotherapy
    32. MILLER DD; LEVY RH; RALEIGH F; LITTRELL RA; STIMMEL GL
      PANEL DISCUSSION

      Pharmacotherapy
    33. BAJPAI M; ROSKOS LK; SHEN DD; LEVY RH
      ROLES OF CYTOCHROME P4502C9 AND CYTOCHROME P4502C19 IN THE STEREOSELECTIVE METABOLISM OF PHENYTOIN TO ITS MAJOR METABOLITE

      Drug metabolism and disposition
    34. ANDERSON GD; YAU MK; GIDAL BE; HARRIS SJ; LEVY RH; LAI AA; WOLF KB; WARGIN WA; DREN AT
      BIDIRECTIONAL INTERACTION OF VALPROATE AND LAMOTRIGINE IN HEALTHY-SUBJECTS

      Clinical pharmacology and therapeutics
    35. MARTIN SW; ELMER GW; VEGA R; MCFARLAND LV; LEVY RH
      PHARMACOKINETICS OF SACCHAROMYCES-BOULARDII WITHIN THE GASTROINTESTINAL-TRACT LUMEN

      Clinical pharmacology and therapeutics
    36. STABLES JP; BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
      PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE

      Epilepsy research
    37. FINNELL RH; BENNETT GD; SLATTERY JT; AMORE BM; BAJPAI M; LEVY RH
      EFFECT OF TREATMENT WITH PHENOBARBITAL AND STIRIPENTOL ON CARBAMAZEPINE-INDUCED TERATOGENICITY AND REACTIVE METABOLITE FORMATION

      Teratology
    38. LEVY RH
      RECENT ADVANCES IN ANTIEPILEPTIC DRUG PHARMACOKINETICS - A SYMPOSIUM - PREFACE

      Epilepsia
    39. LEVY RH
      CYTOCHROME-P450 ISOZYMES AND ANTIEPILEPTIC DRUG-INTERACTIONS

      Epilepsia
    40. LEVY RH; BISHOP F; STREETER AJ; TRAGER WF; KUNZE KL; THUMMEL KT; MATHER GG
      EXPLANATION AND PREDICTION OF DRUG-INTERACTIONS WITH TOPIRAMATE USINGA CYP450 INHIBITION SPECTRUM

      Epilepsia
    41. MATHER GG; KUNZE KL; HARR JE; LEPAGE F; LEVY RH
      PREDICTION OF POTENTIAL-DRUG INTERACTIONS USING CYP450 INHIBITION SPECTRA FOR D2916 AND D3187

      Epilepsia
    42. LEPAGE F; GILLARDIN JM; TOMBRET F; GIRARD P; DESCOMBE JJ; TANG C; MATHER GG; LEVY RH; BAILLIE TA
      HUMAN AND RAT-METABOLISM OF D2916 AND ANTICONVULSANT PROPERTIES OF ITS METABOLITES

      Epilepsia
    43. STEPHENS JR; MATHER GG; LEVY RH
      VALPROATE (VPA) INTERACTION WITH ENDOTOXIN AND TNF

      Epilepsia
    44. MATHER GG; BISHOP FE; TRAGER WF; KUNZE KK; THUMMEL KE; SHEN DD; ROSKOS LK; LEPAGE F; GILLARDIN JM; LEVY RH
      MECHANISMS OF STIRIPENTOL INTERACTIONS WITH CARBAMAZEPINE AND PHENYTOIN

      Epilepsia
    45. VERLEYE M; HEULARD I; STEPHENS JR; LEVY RH; GILLARDIN JM
      EFFECTS OF CITRULLINE MALATE ON BACTERIAL LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA IN RATS

      Arzneimittel-Forschung
    46. ARENDS RHGP; ZHANG KY; LEVY RH; BAILLIE TA; SHEN DD
      STEREOSELECTIVE PHARMACOKINETICS OF STIRIPENTOL - AN EXPLANATION FOR THE DEVELOPMENT OF TOLERANCE TO ANTICONVULSANT EFFECT

      Epilepsy research
    47. ZHANG KY; TANG CY; RASHED M; CUI DH; TOMBRET F; BOTTE H; LEPAGE F; LEVY RH; BAILLIE TA
      METABOLIC CHIRAL INVERSION OF STIRIPENTOL IN THE RAT .1. MECHANISTIC STUDIES

      Drug metabolism and disposition
    48. TANG CY; ZHANG KY; LEPAGE F; LEVY RH; BAILLIE TA
      METABOLIC CHIRAL INVERSION OF STIRIPENTOL IN THE RAT .2. INFLUENCE OFROUTE OF ADMINISTRATION

      Drug metabolism and disposition
    49. ANDERSON GD; ACHEAMPONG AA; LEVY RH
      INTERACTION BETWEEN VALPROATE AND BRANCHED-CHAIN AMINO-ACID-METABOLISM

      Neurology
    50. FINNELL RH; KERR BM; VANWAES M; STEWARD RL; LEVY RH
      PROTECTION FROM PHENYTOIN-INDUCED CONGENITAL-MALFORMATIONS BY COADMINISTRATION OF THE ANTIEPILEPTIC DRUG STIRIPENTOL IN A MOUSE MODEL

      Epilepsia
    51. STEPHENS JR; LEVY RH
      EFFECTS OF VALPROATE AND CITRULLINE ON AMMONIUM-INDUCED ENCEPHALOPATHY

      Epilepsia
    52. KERR BM; THUMMEL KE; WURDEN CJ; KLEIN SM; KROETZ DL; GONZALEZ FJ; LEVY RH
      HUMAN LIVER CARBAMAZEPINE METABOLISM - ROLE OF CYP3A4 AND CYP2C8 IN 10,11-EPOXIDE FORMATION

      Biochemical pharmacology
    53. FINNELL RH; VANWAES M; MUSSELMAN A; KERR BM; LEVY RH
      DIFFERENCES IN THE PATTERNS OF PHENYTOIN-INDUCED MALFORMATIONS FOLLOWING STIRIPENTOL COADMINISTRATION IN 3 INBRED MOUSE STRAINS

      Reproductive toxicology
    54. KLEIN SM; ELMER GW; MCFARLAND LV; SURAWICZ CM; LEVY RH
      RECOVERY AND ELIMINATION OF THE BIOTHERAPEUTIC AGENT, SACCHAROMYCES-BOULARDII, IN HEALTHY-HUMAN VOLUNTEERS

      Pharmaceutical research
    55. PISANI F; HAJYEHIA A; FAZIO A; ARTESI C; OTERI G; PERUCCA E; KROETZ DL; LEVY RH; BIALER M
      CARBAMAZEPINE VALNOCTAMIDE INTERACTION IN EPILEPTIC PATIENTS - IN-VITRO IN-VIVO CORRELATION

      Epilepsia
    56. KROETZ DL; LOISEAU P; GUYOT M; LEVY RH
      IN-VIVO AND IN-VITRO CORRELATION OF MICROSOMAL EPOXIDE HYDROLASE INHIBITION BY PROGABIDE

      Clinical pharmacology and therapeutics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 23:55:25